Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Drugs in Pipeline
11
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
May 12, 2026
20w| Drug Name | Phase |
|---|---|
fruquintinib+sintilimab | Phase 3 |
HMPL-306 Regimen | Phase 3 |
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | Phase 3 |
fruquintinib | Phase 3 |
HMPL-689 | Phase 2 |
Surufatinib in combination with Gemcitabine | Phase 2 |
HMPL-760 planned dose 1 | Phase 2 |
Fruquintinib in Combination with Sintilimab | Phase 2 |
Tazemetostat | Phase 2 |
Surufatinib | Phase 2 |
HMPL-453 | Phase 2 |
1 upcoming, 0 past
Primary completion for HMPL-760 planned dose 1 trial (NCT06601504) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Source